The aim of this study was to determine whether fasting gastric volumes could be reduced by preoperative administration of cisapride. One hundred and twenty-one patients undergoing elective general anaesthesia were randomly allocated to receive either cisapride 20 mg plus diazepam 10 mg or placebo tablets plus diazepam 10 mg, two hours prior to induction. Immediately following induction blind gastric aspiration was performed using a 16Fr multiorificed orogastric tube. Gastric volume, pH, and cisapride blood concentration were measured at this time, Gastric volumes were significantly smaller in the cisapride group, 20.5 (SD 22.2) ml compared to placebo 28.2 (SD 26.0) ml but there was no significant difference with respect to pH. Some patients in both groups had large gastric volumes despite fasting. No significant adverse effects were noted with cisapride.
Pulmonary aspiration of gastric contents has been an important cause of anaesthetic related morbidity from the early days of chloroform anaesthesia to the present dai. The type of gastric residue, volume and pH are important determinants in the pathogenesis and outcome of pulmonary aspiration 2 .] . A variety of methods have been used to prevent aspiration or minimize the effects of gastric contents on the lung. Methods used include: preoperative fasting, cricoid pressure during induction, preoperative nasogastric tube insertion, induced vomiting, H z receptor antagonists (e.g. ranitidine, famotidine), proton pump inhibitors (e.g. omeprazole), dopamine antagonists (e.g. metoclopramide, domperidone) and antacids (e.g. sodium citrate). The fast is the traditional and most widely used method but it does not necessarily result in an empty stomach' and cannot always be undertaken when there is a need for emergency surgery. An agent that would reliably empty the stomach would be extremely valuable in anaesthetic practice.
A gastrointestinal pro kinetic agent, cisapride, was introduced into Australia in 1990. This agent has been shown to be effective in the treatment of gastric stasis secondary to diabetes' or opioid premedication·. Moreover it has been shown to be superior to metoclopramide in reducing morphine-induced gastric stasis'. The administration of cisapride as part of the premedication may therefore improve anaesthetic safety by promoting gastric emptying and reducing fasting gastric volumes.
The aim of the study was to determine whether oral cisapride administered preoperatively with diazepam would reduce fasting gastric aspirates.
MATERIALS AND METHODS
The study was approved by the hospital's Committee on Clinical Investigation. Informed, written consent was obtained from 121 ASA 1 and 2 patients scheduled for elective surgery requiring tracheal intubation. Patients were excluded if there was evidence of active gastrointestinal disease (acute or chronic), previous gastric surgery, concomitant medication that might alter gastric motility (opioids, anticholinergics and tricyclic antidepressants), allergy to cisapride or liver disease. The study was a double-blind, placebocontrolled design. Patients were randomly allocated to two groups-Cisapride: Cisapride 20 mg plus diazepam 10 mg oral, 2 hours preoperatively with 30 ml of water. Placebo:
Cisapride placebo plus diazepam 10 mg oral, 2 hours preoperatively with 30 ml of water.
After fasting overnight, patients received their premedication plus cisapride or placebo orally approximately two hours prior to the anticipated start of surgery. Immediately following induction of anaesthesia, one of the investigators passed a farge 16Fr multiorificed orogastric tube into the stomach. Place~ ment was confirmed by injection of air and auscultation over the epigastrium. The patient was then turned onto his/her right then left side, and then tipped head up and head down to approximately 30 0 to the horizontal. The orogastric tube was aspirated after each change of position. The volume and pH of the gastric aspirate was measured; it was not returned to the stomach.
Gastric volume and pH
The sample volume was measured using a graduated 50 ml syringe (Terumo, Australia) and the pH was measured using an Orion model SA 720 pH meter calibrated prior to measurements.
Cisapride blood drug concentration
Ten millilitres of venous blood was collected immediately prior to induction of anaesthesia. This sample was centrifuged within 15 minutes and the plasma frozen. These samples were subsequently analysed and plasma cisapride concentration was determined by HPLC using a modification of the method of Woestenborghs 8 with a limit of sensitivity of 2 ng.ml-I •
Clinical Evaluation
Patients' demographic data were recorded along with preoperative and perioperative pulse and blood pressure.
Statistical Analysis
Outcome measures for cisapride and placebo groups were compared using Mann-Whitney U tests. A P value of less than 0.05 was accepted as indicating a significant result.
RESULTS
One hundred and twenty-one patients were enrolled into the study. One patient, though enrolled in the study, did not receive the study tablets and was withdrawn. Three further patients were subsequently found to be taking tricyclic antidepressants, one to be lactating and one to be above the upper age limit (70 years) for the study; these patients were excluded from analyses.
Demographic data of both groups are shown in Table  1 administration and gastric aspiration was: cisapride 122 min (range 45-270 min), placebo 154 min (range 70-375 min). The mean gastric volume among patients who received cisapride was significantly smaller compared with the placebo control (p=0.028, Mann-Whitney U test). There were four patients in the cisapride group and six in the placebo group with gastric volumes > 0.8 ml.kg -I. One patient in the cisapride group had a gastric volume greater than 100 ml compared with two in the placebo group. There were however no differences in pH of the aspirates between the two groups ( Table 2 ). There was no difference noted between the groups with respect to reported side-effects, however baseline (preinduction) heart rate was higher in the cisapride group (P=0.006) ( 
DISCUSSION
The results of this study have shown that oral cisapride can reduce the residual gastric volumes in patients presenting for elective surgery.
A Swedish survey recently reported their experience of perioperative pulmonary aspiration, which had an overall incidence of 1 in 2131 anaesthetics". Although risk factors such as emergency procedures, impaired gastric emptying and active gastrointestinal disease were implicated in 80070 of cases of pulmonary aspiration, there remained 1 in 5 cases in which aspiration occurred in "low-risk" elective operations. Moreover the critical volume and pH that causes significant pulmonary damage is still not clear. Little work has been done in defining such values; indeed the often quoted 0.4 ml.kg-1 and pH <2.5 was based on one experiment in a monkey3 and a subsequent study has indicated that this critical volum'e may be at least double this (0.8 ml.kg-l)IO. Even with this more conservative estimate, four patients in the cisapride group and six in the placebo group were in the "high-risk" subgroup of patients.
Cisapride has little effect on release of gastrin 11 and does not alter the normal composition of gastric secretions 12 • Therefore in this study we are assuming that enhancement of gastric motility is reflected by reduction in gastric volume. There are many methods employed which assess gastric motility. Indirect methods include absorption kinetics of orally administered drugs such as paracetamol, while direct assessment include scintigraphy, gastric ultrasound, applied potential tomography, electrogastrography and gastroduodenal manometry. The evaluation of gastric volume from aspiration via a nasogastric tube is another effective method of comparing two treatment regimens. Whereas methods such as scintigraphy and ultrasound may be more accurate, they are unsuitable when large numbers of patients are required. Comparing blind aspiration to direct gastric aspiration via an endoscope, Taylor showed that absolute volumes were underestimated by approximately 14 ml or on average 53% of the true volume when aspirated under direct vision". However, this underestimation should be similar between the two groups in this study and hence any significant difference noted would be valid in comparing two such groups. The inhibition of normal gastrointestinal motility following anaesthesia has been implicated as one of the causative factors in postoperative nausea and vomiting. The importance of evacuation of stomach contents following induction of anaesthesia on postoperative nausea and vomiting is debated 14 • 15 • Cisapride enhances gastric motility and causes a reduction in fasting gastric volumes. In addition an antiemetic effect in post-prandial nausea and vomiting l6 has been demonstrated. Whilst the design of the present study could not allow interpretation of nausea and vomiting data, further investigation is warranted to identify the importance of cisapride in alleviating this problem.
In this study, cisapride reduced mean fasting gastric volumes by over one quarter, and whilst this is statistically significant, it is far from effective in producing a completely empty stomach prior to anaesthesia. In addition some patients in both groups were found to have a quite large residual gastric volume. Diabetic patients are known to have impaired gastric emptying leading to larger fasting gastric volumes. Feldman described the effectiveness of intravenous cisapride in augmenting gastric emptying of indigestible solids in diabetic patients s . However a recent randomized double-blind study failed to demonstrate any difference in gastric volume between placebo and oral cisapride in diabetic patients following induction of anaesthesia". This study however may be flawed by its small sample size and relative underdosage of cisapride 1s • In summary, cisapride administered as part of premedication for elective surgery significantly reduced mean gastric volume by approximately 29%. Further work is needed to evaluate the clinical significance of such a reduction in gastric volume, along with its role in reducing fasting gastric volumes in diabetic patients and prevention of postoperative nausea and vomiting.
